Ponatinib in CML and Ph+ ALL: balancing high efficacy with vascular safety

Chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) are driven by the BCR:ABL1 fusion and remain highly responsive to tyrosine kinase inhibitors (TKIs). Ponatinib, a third-generation TKI, uniquely retains activity against the T315I 'gatekeeper' mutation and most other BCR:ABL1 variants, producing deep cytogenetic and molecular responses in resistant CML and improving survival in Ph+ ALL. Across the PACE and OPTIC programs, frontline Ph+ ALL combinations (hyper-CVAD- and blinatumomab-based), and real-world cohorts, ponatinib demonstrates robust antileukemic efficacy in diverse settings and after multiple prior TKIs. However, its multikinase profile confers a clinically meaningful risk of arterial occlusive events (AOEs)-including coronary, cerebrovascular, and peripheral arterial complications-whose incidence is shaped by baseline cardiovascular risk and overall drug exposure. Mechanistic studies suggest that endothelial dysfunction, pro-inflammatory signaling, impaired nitric oxide bioavailability, and microvascular rarefaction contribute to ponatinib-associated vascular toxicity. Clinically, response-based dosing-such as step-down from 45→30→15 mg in CML or 30→15 mg in Ph+ ALL upon molecular milestones-preserves efficacy while reducing exposure-related AOE risk, though events are not eliminated. Emerging cardio-oncology strategies can further mitigate harm: baseline risk stratification (e.g. SCORE2/SCORE2-OP, HFA-ICOS), aggressive management of blood pressure and lipids, selective antiplatelet prophylaxis in high-risk profiles, and close longitudinal surveillance. Overall, contemporary evidence supports ponatinib as a high-potency option for T315I disease and multi-tyrosine kinase inhibitor (TKI) resistance, and as a practical component of modern Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) therapy, provided that dosing is individualized and cardiovascular risk is proactively managed. Future priorities include refining patient selection, validating preventive cardio-oncology bundles, and defining minimal-effective exposure thresholds that sustain durable disease control with the lowest feasible vascular liability.